Allogene Therapeutics, Inc.·4/A

Apr 2, 4:11 PM ET

Chang David D 4/A

4/A · Allogene Therapeutics, Inc. · Filed Apr 2, 2021

Insider Transaction Report

Form 4/AAmended
Period: 2021-03-26
Chang David D
DirectorPresident and CEO
Transactions
  • Gift

    Common Stock

    2020-08-31+205,778856,044 total(indirect: See footnote)
  • Gift

    Common Stock

    2020-08-31+205,778856,044 total(indirect: See footnote)
Holdings
  • Common Stock

    (indirect: See footnote)
    1,201,108
  • Common Stock

    2,284,869
Footnotes (5)
  • [F1]Securities held in the name of the Chang 2006 Family Trust.
  • [F2]On August 31, 2020, Julia Chang transferred 205,778 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary.
  • [F3]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
  • [F4]On August 31, 2020, Robert Chang transferred 205,778 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary.
  • [F5]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.

Documents

1 file
  • 4
    marketforms-52165.xml

    PRIMARY DOCUMENT